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Background. The World Health Organization recommends GeneXpert MTB/RIF Ultra (Xpert Ultra), a fully automated poly-
merase chain reaction (PCR) assay, as the initial tuberculous meningitis (TBM) diagnostic test. The assay’s PCR cycle threshold (Ct) 
values represent the number of PCR cycles required for probe signal to be detected (low Ct value = high bacillary load) and may 
approximate tuberculosis (TB) bacillary load. We measured the relationship between cerebrospinal fluid (CSF) TB bacillary load 
with mortality. 
Methods. We prospectively enrolled 102 human immunodeficiency virus (HIV)–positive Ugandans with probable or definite 
TBM from April 2015 to August 2019. Xpert Ultra Ct tertiles and semi-quantitative categories were separately analyzed as predictors 
of 2-week mortality. We investigated associations between Ct and baseline clinical and CSF parameters. 
Results. Subjects with Ct values in the low tertile (ie, high bacillary load) had 57% 2-week mortality—worse than the interme-
diate (17%) and high (25%) Ct tertiles and Xpert Ultra–negative (30%) probable TBM cases (P = .01). In contrast, the reported semi-
quantitative Xpert Ultra categorization was less precise; with the medium to low category trending toward worse 2-week survival 
(42%) compared with very low (28%), trace (26%), and negative (30%) categories (P = .48). Ct tertile was significantly associated 
with baseline CSF lactate (P = .03). 
Conclusions. High CSF TB bacillary load, as measured by Xpert Ultra Ct tertile, is associated with an almost 2-fold higher 
2-week mortality in HIV-associated TBM and is a better predictor than the reported Xpert Ultra semi-quantitative category. Xpert 
Ultra Ct values could identify TBM patients at increased risk of death who may benefit from enhanced supportive care.
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Tuberculosis (TB) accounts for approximately 1.3 million 
deaths from 10 million new cases annually worldwide, with the 
highest burden in sub-Saharan Africa [1]. Tuberculous menin-
gitis (TBM) occurs in approximately 1%–5% of global TB cases 
and is the second leading cause of meningitis in many African 
settings [2–5]. TBM has a devastating impact, with approxi-
mately 40% in-hospital mortality and up to 60% of survivors 
left with neurological disability [6, 7].
TBM is notoriously challenging to diagnose, often relying 
upon clinical suspicion, which may contribute to high mor-
tality. Historically, cerebrospinal fluid (CSF) culture has been 
the mainstay of confirmatory testing, which takes at least 
2 weeks to provide results, often too late to impact clinical 
management [8]. The development of the Xpert MTB/RIF 
assay (Xpert) was a major step forward in TBM diagnosis. 
This fully automated, cartridge-based polymerase chain re-
action (PCR) assay provides a semi-quantitative result within 
2 hours. The newer Xpert MTB/RIF Ultra (Xpert Ultra, 
Cepheid, Sunnyvale, California), a reengineered version of 
Xpert using the same platform, was recommended by the 
World Health Organization in 2017 [9]. Ultra has improved 
sensitivity compared to the original Xpert; a recent study in 
a cohort of Ugandan human immunodeficiency virus (HIV)–
positive adults with TBM demonstrated a 76.5% sensitivity 
for probable/definite TBM compared to 45% and 43% for 
Xpert and culture, respectively [8, 10].
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The reason for Xpert Ultra’s improved sensitivity is its lower 
limit of detection of 16 colony-forming units per milliliter 
(CFUs/mL), vs 114 CFUs/mL for Xpert [11]. This is achieved 
primarily by incorporating a larger PCR reaction chamber and 
adding 2 multicopy Mycobacterium tuberculosis DNA amplifi-
cation targets (IS6110 and IS1081), in addition to the 4 probes 
directed at mutations in the rifampicin resistance–determining 
region of the rpoB gene (rpoB1–4) [9]. The PCR cycle threshold 
(Ct) values represent the number of PCR cycles required for 
each probe signal to reach a detection threshold and may ap-
proximate TB bacillary load. When DNA amplification reaches 
the detection threshold at any of the targets, the result “MTB 
detected” is given, and depending on the Ct values and config-
uration of probe positivity, 5 semi-quantitative categories of TB 
bacillary load are reported: trace, very low, low, medium, and 
high [9]. A nuance of the Ultra assay is that a “trace” category 
result occurs when rpoB probes are negative and IS6110/IS8110 
probes are positive, regardless of the Ct value. This nuance may 
make Ct value a better correlate of bacillary load than the semi-
quantitative category.
Various methods have been used to estimate TB bacillary 
load, including time to culture positivity, Ziehl-Neelsen smear 
microscopy, and M. tuberculosis molecular bacterial load assay 
[12]. One study found that time to CSF culture positivity is 
independently associated with mortality in HIV-negative pa-
tients (hazard ratio, 1.37 [95% confidence interval, 1.02–1.84]), 
suggesting that an increased bacterial load may be associated 
with worse outcomes [13]. However, these methods are time 
consuming, are difficult to apply to TBM due to paucibacillary 
CSF, and are not widely available in low- and middle-income 
countries; thus, their role in TBM is uncertain. Xpert and Xpert 
Ultra provide new opportunities to investigate the relationship 
of bacillary burden and outcome in TBM. We have recently 
shown that the Xpert Ultra semi-quantitative category correl-
ates with days to CSF culture positivity [8]. In addition, a recent 
study found that high CSF TB bacillary load, as measured by 
Xpert Ct value, was associated with increased disease severity, 
CSF neutrophil count, and CSF cytokine concentrations and 
predicted new neurological events after starting treatment, but 
not death [14]. With the introduction of the new, more sensitive 
Xpert Ultra, and in a population of predominantly HIV-positive 
persons in Uganda with TBM, we examined whether CSF TB 
bacillary load was associated with clinical outcome and CSF bi-
ochemical or cellular parameters.
MATERIALS AND METHODS
Study Setting and Population
We prospectively evaluated adults aged ≥18  years suspected 
to have meningitis presenting to Mulago National Referral 
Hospital and Mbarara Regional Referral Hospital in Uganda 
between April 2015 and August 2019 as part of the screening 
process for 2 clinical trials (XXX [ASTRO-CM]: NCT01802385 
and High-Dose Intravenous and Oral Rifampicin to 
ImproveSurvival of Adult Tuberculous Meningitis [RifT]: 
ISRCTN42218549). The parent trials received relevant institu-
tional review board and regulatory approvals, and all partici-
pants or surrogates (in the case of altered mental status) gave 
informed consent for lumbar puncture and storage of samples 
for future research purposes.
Uniform Clinical Case Definition
Subjects with probable or definite TBM as defined by the con-
sensus uniform clinical case definition were included. Definite 
TBM includes any CSF positivity by microscopy, culture, or 
PCR. Probable TBM cases have negative CSF TB microbiology 
but reach a score of >12 points or >10 points with or without 
brain imaging, respectively, based on clinical, radiological, and 
CSF criteria and evidence of confirmed TB in another anatom-
ical location [15].
CSF Testing
CSF samples from diagnostic lumbar punctures were tested 
at the bedside for cryptococcal antigen (CrAg lateral flow 
assay; IMMY, Norman, Oklahoma), glucose (OneTouch 
Select glucose meter, Lifescan, Inverness, United Kingdom), 
and lactate (Lactate Plus Meter, Nova Biomedical, Waltham, 
Massachusetts). Approximately 1 mL of CSF was sent for rou-
tine testing (cell count and differential, protein, Gram stain, and 
culture). Patients without cryptococcal meningitis (CSF CrAg 
negative) were evaluated for TBM. With regard to TBM testing, 
from February 2015 to December 2018 the remaining sample 
was centrifuged at 3000g for 20 minutes. Surplus supernatant 
was removed and the cell pellet was resuspended in 2 mL of su-
pernatant and divided between Xpert, Xpert Ultra, and myco-
bacterial growth inhibitor tube (BacTec 960, Becton Dickinson, 
Franklin Lakes, New Jersey). For samples collected in 2019, an 
uncentrifuged 2-mL CSF sample was tested with Xpert Ultra.
Study Treatment and Follow-up
Following TBM diagnosis, all patients were treated with rifam-
picin, isoniazid, pyrazinamide, ethambutol, and adjunctive cor-
ticosteroids (dexamethasone 0.4 mg/kg/day in week 1, 0.3 mg/
kg/day in week 2, then tapered over 2 months). During the ma-
jority of our diagnostic study period, the follow-up duration 
was 2 weeks. Research medical officers recorded a clinical as-
sessment and baseline demographics on day 1, and vital status 
at 2 weeks. From 14 January 2019, eligible participants were 
enrolled into the RifT trial, a phase 2 pharmacokinetic study 
investigating high-dose rifampicin. For the purposes of this 
analysis, follow-up was limited to 2 weeks, since only a minority 
of participants had longer-term follow-up after January 2019.
Statistical Analysis
We used Ct values from the multicopy amplification targets 
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load. A positive Xpert Ultra result always yields a Ct value for the 
IS6110/IS1081 targets; hence, these were used for analysis rather 
than the rpoB targets, which were negative in 27 of 71 positive Xpert 
Ultra results. A high Ct value signifies an increased number of PCR 
amplification cycles required for TB detection, and therefore may 
correlate with a low bacillary load. Ct values were categorized into 
tertiles: low (16.2–20.0), intermediate (20.1–25.0), high (25.1–32.7), 
and negative. Participants with a negative value were assigned an 
artificially high Ct value of 40 for analysis purposes. Baseline char-
acteristics were compared across all categories with Kruskal-Wallis 
tests for continuous variables and χ 2 tests for categorical variables. 
Two-week survival was plotted via Kaplan-Meier curves for Ct 
tertiles and negative Xpert Ultra and compared via a log-rank test. 
A second Kaplan-Meier plot was calculated for semi-quantitative 
values (trace, very low, medium-low, and negative). Medium and 
low were grouped together due to small number of participants in 
those categories. All statistical analysis was done with SAS version 
9.4 software (SAS Institute, Cary, North Carolina).
RESULTS
CSF samples from 102 adults with TBM were tested with 
Xpert Ultra. One participant was excluded due to a missing 
semi-quantitative category result; of the remaining 101 parti-
cipants, 70 (69%) had a positive Xpert Ultra and 31 (31%) had 
a negative result. The semi-quantitative category results were as 
follows: 0 high, 5 medium, 20 low, 18 very low, and 27 trace. Of 
the 31 participants with a negative Xpert Ultra, 5 had a positive 
CSF culture and 1 had a positive acid-fast smear. The median 
age of participants was 32 (interquartile range [IQR], 29–38) 
years, and 40% were women. The study population were 95% 
HIV-positive with a median CD4 of 78 (IQR 37–131) cells/μL, 
and 50% of participants were receiving antiretroviral therapy 
(ART) at presentation for a median duration of 4.4  months. 
The British Medical Research Council (BMRC) TBM grade 
was grade 2 or 3 for 91% of participants at enrollment. Baseline 
demographics did not significantly differ between Ct tertiles 
(Table 1).
Ninety-nine participants were included in the survival 
analysis, since 2 participants were missing outcome data. 
Participants with a CSF Xpert Ultra Ct value result in the low 
tertile (ie, high bacillary load) had a 57.1% 2-week mortality, 
significantly worse than other categories (log-rank P = .01; 
Figure  1). The lowest 2-week mortality was found within the 
intermediate Ct tertile group (16.7%). Participants within the 
Table 1. Comparison of Baseline Demographics, Clinical Features, and Cerebrospinal Fluid Biochemical and Cellular Parameters According to GeneXpert 
MTB/RIF Ultra Cycle Threshold Tertile Categories
Characteristic
Low Tertile (Ct 16.2–20.0)  
(n = 22)
Intermediate Tertile (Ct 20.1–25.0)  
(n = 24)
High Tertile (Ct 25.1–32.7)  
(n = 24) P Valuea
Baseline demographics
 Age, y 32 (29–36) 34 (32–38) 31 (28–37) .26
 Sex, female 10 (46%) 10 (42%) 7 (29%) .49
HIV details
 HIV positive 20 (91%) 23 (96%) 24 (100%) .31
 Currently on ART 10 (48%) 12 (52%) 13 (54%) .91
 Months on ARTb,c 9.7 (3.1–22.2) 2.3 (0.3–7.0) 1.1 (0.7–3.4) .18
 CD4 countc, cells/μL 58 (48–73) 89 (56–210) 59 (14–117) .36
Clinical details
 Focal neurological deficit 5 (23%) 4 (17%) 10 (42%) .13
 Fever 18 (82%) 19 (79%) 20 (83%) .65
BMRC TBM grade
 1 2 (10%) 5 (21%) 2 (9%) .46
 2 13 (62%) 16 (67%) 14 (61%)  
 3 6 (29%) 3 (13%) 7 (30%)  
Baseline CSF characteristics
 Total WBC countc, cells/μL 80 (4–245) 35 (4–250) 35 (4–165) .50
 % lymphocytes 95 (65–100) 85 (69–100) 93 (65–100) .92
 Opening pressurec, mm H2O 190 (100–270) 230 (100–290) 205 (130–300) .97
 Proteinc, mg/dL 118 (46–208) 156 (90–316) 144 (101–200) .58
 Lactatec, mmol/L 10.6 (9.5–12.0) 7.6 (6.9–9.5) 7.4 (4.6–9.8) .03
 Glucosec, mg/dL 27 (18–33) 32 (18–70) 30 (21–60) .44
Data are presented as median (interquartile range) or no. (%).
Abbreviations: ART, antiretroviral therapy; BMRC, British Medical Research Council; CSF, cerebrospinal fluid; Ct, Xpert Ultra polymerase chain reaction cycle threshold; HIV, human immuno-
deficiency virus; TBM, tuberculous meningitis; WBC, white blood cell. 
aKruskal-Wallis for medians; χ 2 test for proportions. 
bAmong those on ART at diagnosis. 
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high Ct tertile (low bacillary load) had a lower 2-week mor-
tality than the negative Xpert Ultra group (25.0% and 30.0%, 
respectively).
In the survival analysis based on Xpert Ultra semi-quantitative 
categories, participants in the medium and low groups (com-
bined) trended toward higher 2-week mortality (42%) com-
pared with very low (28%), trace (26%), and negative (30%) 
persons (log-rank P = .48; Figure 2). We replotted Kaplan-Meier 
survival curves for both Ct tertiles and semi-quantitative values 
in a sensitivity analysis excluding the 6 persons with negative 
CSF Xpert Ultra, but with a positive culture or smear result. 
For both Ct tertiles and semi-quantitative groups, the mortality 
remained the same, except in the Ultra negative group where 
mortality decreased from 30% to 25% in both analyses. The log-
rank P values remained relatively unchanged for both Ct tertiles 
and semi-quantitative groups (P = .01 and .41, respectively).
The Ct tertile was not associated with HIV status (P = .31), 
baseline CD4 cell count (P = .36), or the percentage of parti-
cipants on ART (P = .91). Participants in the low Ct tertile 
group (high bacillary load) had a median ART duration of 
9.7 months, whereas participants in the intermediate and high 
Ct tertile groups trended toward a shorter median duration of 
ART therapy (2.3 and 1.1  months, respectively), though this 
difference was not statistically significant (P = .18). There was 
no association with clinical features such as fever (P = .65), 
BMRC TBM severity grade (P = .46), or focal neurologic deficit 
(P = .13). With respect to baseline CSF parameters, there was a 
significant difference observed between Ct tertiles in CSF lac-
tate, with the highest lactate observed in the low Ct tertile (high 
bacillary load) (P = .03). There were no differences between Ct 
tertiles in opening pressure (P = .97), protein (P = .58), total 
white blood cell (WBC) count (P = .50), or glucose (P = .44) 
(Table 1).
DISCUSSION
In our study of HIV-associated TBM, low Ct tertile value (high 
CSF TB bacillary load), as measured by Xpert Ultra, was asso-
ciated with an almost 2-fold increased mortality compared to 
those with intermediate and high Ct tertiles. An intermediate 
CSF Ct tertile value was associated with the most favorable 
2-week outcome. Interestingly, association of 2-week mortality 
was statistically significant for Ct tertiles but not for semi-
quantitative categories. There was a significant difference in 
CSF lactate between Ct tertiles.
In 2019, Thuong et  al investigated the association between 
pretreatment CSF TB bacillary load by Xpert Ct value and TBM 
outcome in 692 Vietnamese adults [14]. This study found that 
higher bacterial loads were associated with increased disease se-
verity (TBM grade 1 vs 3: odds ratio, 1.59; P = .001), increased 
CSF neutrophil count (r = .364; P < .0001), and 10 measured 
cytokine concentrations (r = .438; P < .0001) [14]. In addi-
tion, high TB bacillary load predicted new neurological events 
after treatment initiation but not death. In contrast, our data 
suggested an association between bacillary load and 2-week 
mortality but did not find an association with disease severity 
(by BMRC TBM severity grade) or focal neurological deficit. 
We also did not observe an association between CSF Ct tertile 
and CSF inflammation. However, potential comparison be-
tween studies is limited by measurement of different surrogate 
Figure 2. Two-week survival by Xpert MTB/RIF Ultra semi-quantitative value 
among participants with probable or definite tuberculous meningitis (TBM) in 
Kaplan-Meier model. Mortality by subgroup was as follows: medium/low, 42% 
(10/24); very low, 28% (5/18); trace, 26% (7/27); and negative Ultra, 30% (9/30).
Figure 1. Two-week survival by Xpert MTB/RIF Ultra polymerase chain reaction 
cycle threshold (Ct) level among participants with probable or definite tuberculous 
meningitis (TBM) in Kaplan-Meier model. Mortality by subgroup was as follows: 
low Ct tertile, 57% (12/21); intermediate Ct tertile, 17% (4/24); high Ct tertile, 25% 
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markers of inflammation (CSF protein and WBC count in 
Uganda vs CSF neutrophil and cytokine concentrations in 
Vietnam), differences in HIV prevalence between populations 
(which can affect the cellularity of CSF and neutrophil count 
in HIV-associated TBM), and our smaller sample size, making 
marginal associations more difficult to measure [16–18]. 
Further divergent results may be due to the use of Xpert Ultra, 
rather than the original Xpert. It is possible that we were able 
to draw distinctions in mortality because we could detect more 
cases with lower CSF bacillary load. In addition, our cohort of 
mainly HIV-positive Ugandans presenting with severe disease 
was markedly different to the Vietnamese study, in which 58% 
were HIV negative and 38% presented with TBM grade 1. This 
distinct cohort may have different host responses and CSF bac-
illary loads. Another important geographic consideration is 
variation in the copy number of IS6110 and IS1081 sequences 
present within local M. tuberculosis strains, which supports fur-
ther validation of this work in different populations before it is 
considered as a prognostic biomarker.
Our observation that Ct tertiles, rather than semi-quantitative 
values, are a better predictor of mortality could be explained 
by the nature of the in-built semi-quantitative categorization 
process. The semi-quantitative Xpert Ultra categories are deter-
mined by the configuration of positivity of 4 rpoB probes and 
multicopy amplification targets IS6110/IS1081. A “trace” cate-
gory occurs if the rpoB probes are negative, regardless of the IS 
Ct values [9]. Data from the current study suggest that looking 
at Xpert Ultra IS6110/IS1081 Ct values may be a better predictor 
of mortality compared with the semi-quantitative category.
We report that participants with an intermediate Ct tertile 
had the most favorable 2-week outcome, followed by those 
with low CSF TB burden (high Ct tertile and negative Xpert 
Ultra). The worst outcome occurred in patients within the low 
Ct tertile group (high bacillary load). It is noteworthy that those 
with lowest CSF bacillary burden appear to have worse out-
comes than those with an intermediate bacillary load. It is pos-
sible that this difference may change with a larger sample size. 
However, this may also represent an excessive immune response 
that successfully curtails bacterial replication but leaves a trail 
of immunopathology in its wake. Studies suggest that adverse 
outcomes are associated with both an excessive and inadequate 
immune response in TBM, and the same is true in cryptococcal 
meningitis where the damage-response parabola has been well 
described [19]. For example, HIV-negative Vietnamese adults 
with TBM had an increased mortality when they possessed a 
single-nucleotide polymorphism in the LTA4H rs17525485 
allele, resulting in either a hyper- or hypo-inflammatory state 
[16]. Worse outcomes have also been associated both with high 
CSF neutrophils in an Indonesian, predominantly HIV-negative 
cohort, and conversely with acellular CSF in adults with HIV-
associated TBM in Uganda [13, 18]. Therefore, it is conceiv-
able that mortality differences observed in our study reflect the 
varying host immune response, which either curtails bacillary 
replication through an excessive inflammatory response with 
ensuing tissue damage or allows unchecked TB replication in 
the CSF due to a paucity of inflammatory response. CSF cyto-
kine and other studies of host response would be helpful in fur-
ther understanding these findings.
We observed a significant difference in CSF lactate across 
Ct tertiles, with the highest CSF lactate observed in the low Ct 
tertile group (ie, highest bacillary load). Previous studies sug-
gest that lactate levels between 5 and 10 mmol/L support a diag-
nosis of TBM and high initial lactate levels are associated with 
death [20]. Further investigation is required into the utility of 
CSF lactate as a potential diagnostic and prognostic biomarker 
in TBM. Our data also reveal a nonsignificant trend toward 
shorter duration of ART in participants within the interme-
diate and high Ct tertile groups (intermediate and low bacillary 
loads). This difference may be explained by unmasking immune 
reconstitution inflammatory syndrome (IRIS), although formal 
IRIS case adjudication was not performed. Further work to 
carefully characterize unmasking TBM-IRIS with correlations 
to Xpert Ultra results is required.
A limitation of this study is that 17 of 101 participants received 
high-dose rifampicin as part of a clinical trial. However, these 
participants were distributed evenly across Ct tertile groups 
(P = .93). In addition, there is currently no definitive evidence 
that high-dose rifampicin impacts survival, and final analysis 
of the parent study did not identify differences in mortality be-
tween arms (unpublished data) [21, 22]. Another limitation is 
the relatively small cohort size, which may have reduced the 
power to detect secondary associations. Furthermore, we used 
Ct value as a surrogate for bacillary load (in the absence of an ef-
fective bacillary load assay), but this may be an imperfect proxy. 
Our analysis was limited to 2-week follow-up, which is justified 
by the significant early mortality in TBM described in the liter-
ature [13, 23]. Whether this association with acute 2-week mor-
tality translates into ongoing differential mortality in the longer 
term should be studied in future observational cohorts. In ad-
dition, further work including correlation of Ct tertiles with 
clinical descriptions of IRIS and immunological studies, such 
as cytokine studies or transcriptomics, may help further explain 
our findings. As this is a first report of Xpert Ultra Ct values 
being used as a predictor of outcomes in TBM, our observation 
requires independent confirmation in non-HIV populations, in 
other geographical settings, and in larger cohorts.
In conclusion, we report that a low Xpert Ultra Ct tertile (high 
CSF TB bacillary load) is associated with increased mortality in 
HIV-associated TBM and that Ct tertiles are more accurate in 
predicting early TBM-related mortality than Xpert Ultra semi-
quantitative categories alone. This study raises the possibility of 
Xpert Ultra Ct values being used to identify patients at greatest 
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